Real-world safety data from patients with rheumatic diseases treated with CT-P13, an infliximab biosimilar: an interim analysis from an observational study
<p><strong>Background</strong> CT-P13, an infliximab biosimilar, has been available in Europe and Canada since 2015, and real-world experience with CT-P13 is important to support the safety of this medication. PERSIST is an ongoing, observational cohort study evaluating CT-P13 as...
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Conference item |
| Vydáno: |
BMJ Journals
2019
|